PD: A biological membrane and a non-biological fluid

Contributions to Nephrology

Volumn 140, Issue , 2003, Pages 1-9

  Jörres, Achim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 26144440717     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (71)

1. Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990;37:1563-1570.
2. Jörres A, Ludat K, Lang J, Sander K, Gahl GM, Frei U, DeJonge K, Williams JD, Topley N: Establishment and functional characterization of human peritoneal fibroblasts in culture: Regulation of interleukin-6 production by proinflammatory cytokines. J Am Soc Nephrol 1996;7: 2192-2201.
3. Beavis MJ, Williams JD, Hoppe J, Topley N: Human peritoneal fibroblast proliferation in threedimensional culture: Modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney Int 1997;51:205-215.
4. Mortier S, De Vriese AS, Van DV, Schaub TP, Passlick-Deetjen J, Lameire NH: Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: Role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002; 13:480-489.
5. Lameire N, Van Biesen W, Van Landschoot M, Wang T, Heimbürger O, Bergström J, Lindholm B, Hekking LP, Havenith CE, Beelen RH: Experimental models in peritoneal dialysis: A European experience. Kidney Int 1998;54:2194-2206.
6. Topley N, Mackenzie RK, Jörres A, Coles GA, Davies M, Williams JD: Cytokine networks in continuous ambulatory peritoneal dialysis: Interactions of resident cells during inflammation in the peritoneal cavity. Perit Dial Int 1993;13(suppl 2):282-285.
7. Topley N, Williams JD: Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int Suppl 1994;48:71-78.
8. Jörres A, Ludat K, Sander K, Dunkel K, Lorenz F, Keck H, Frei U, Gahl GM: The peritoneal fibroblast and the control of peritoneal inflammation. Kidney Int Suppl 1996;56:22-27.
9. Witowski J, Jörres A, Coles GA, Williams JD, Topley N: Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney Int 1996;50:1212-1223.
10. Topley N, Brown Z, Jörres A, Westwick J, Davies M, Coles GA, Williams JD: Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-lβ and tumor necrosis factor-α. Am J Pathol 1993; 142:1876-1886.
11. Betjes MG, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hart M, Beelen RH: Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis factor-α, interleukin-1, and medium conditioned by macrophages cocultured with Staphylococcus epidermidis. J Infect Dis 1993;168:1202-1210.
12. Li FK, Davenport A, Robson RL, Loetscher P, Rothlein R, Williams JD, Topley N: Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression. Kidney Int 1998;54:2170-2183.
13. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, Polubinska A, Friess H, Gahl GM, Frei U, Jörres A: IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GROα chemokine from mesothelial cells. J Immunol 2000;165: 5814-5821.
14. Witowski J, Thiel A, Dechend R, Dunkel K, Fouquet N, Bender TO, Langrehr JM, Gahl GM, Frei U, Jörres A: Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: Induction by macrophage-derived cytokines. Am J Pathol 2001;158:1441-1450.
15. Rollins BJ: Chemokines. Blood 1997;90:909-928.
16. Tekstra J, Visser CE, Tuk CW, Brouwer-Steenbergen JJ, Burger CW, Krediet RT, Beelen RH: Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. J Am Soc Nephrol 1996;7:2379-2384.
17. Betjes MG, Visser CE, Zemel D, Tuk CW, Struijk DG, Krediet RT, Arisz L, Beelen RH: Intraperitoneal interleukin-8 and neutrophil influx in the initial phase of a CAPD peritonitis. Perit Dial Int 1996;16:385-392.
18. Zemel D, Krediet RT, Koomen GCM, Kortekaas WMR, Geertzen HGM, ten Berge RJM: Interleukin-8 during peritonitis in patients treated with CAPD: An in-vivo model of acute inflammation. Nephrol Dial Transplant 1994;9:169-174.
19. Yung S, Davies M: Response of the human peritoneal mesothelial cell to injury: An in vitro model of peritoneal wound healing. Kidney Int 1998;54:2160-2169.
20. Rubin J, Herrera GA, Collins D: An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991;18:97-102.
21. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-479.
22. Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996;11:498-506.
23. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001;12:1046-1051.
24. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, Aguilera A, Sanchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, Del Peso G, Cirujeda A, Gamallo C, Sanchez-Madrid F, Lopez-Cabrera M: Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003;348:403-413.
25. Duwe AK, Vas SI, Weatherhead JW: Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immun 1981;33: 130-135.
26. Jörres A, Gahl GM, Frei U: Peritoneal dialysis fluid biocompatibility: Does it really matter? Kidney Int Suppl 1994;48:79-86.
27. Holmes CJ: Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993;13:88-94.
28. Topley N, Coles GA, Williams JD: Biocompatibility studies on peritoneal cells. Perit Dial Int 1994;14(suppl 3):21-28.
29. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD: Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995;47:282-293.
30. Jörres A, Bender TO, Finn A, Witowski J, Fröhlich S, Gahl GM, Frei U, Keck H, Passlick-Deetjen J: Biocompatibility and buffers: Effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998;54:2184-2193.
31. Jörres A, Williams JD, Topley N: Peritoneal dialysis solution biocompatibility: Inhibitory mechanisms and recent studies with bicarbonate-buffered solutions. Perit Dial Int 1997; 17(suppl 2):42-46.
32. Topley N, Kaur D, Petersen MM, Jörres A, Passlickh-Deetjen J, Coles GA, Williams JD: Biocompatibility of bicarbonate-buffered peritoneal dialysis fluids: Influence on mesothelial cell and neutrophil function. Kidney Int 1996;49:1447-1456.
33. Topley N, Kaur D, Petersen MM, Jörres A, Williams JD, Faict D, Holmes CJ: In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996;7:218-224.
34. Alscher DM, Pauli-Magnus C, Kirchgessner J, Kuhlmann U, Mettang T: A new lactate-based, plasticizer-free, neutral peritoneal dialysis fluid provided in a two-compartment system: Effect on peripheral leukocyte function. Nephron 2000;86:62-69.
35. Topley N: In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int 1997; 17:42-47.
36. Jörres A: Innovative approaches to the preservation of the peritoneal membrane: From bench to bedside. Adv Ren Replace Ther 2001;8:164-172.
37. Gotloib L, Wajsbrot V, Shostak A, Kushnier R: Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid. Nephron 1996;73:219-227.
38. Gotloib L, Shostak A, Wajsbrot V: Detrimental effects of peritoneal dialysis solutions upon in vivo and in situ exposed mesothelium. Perit Dial Int 1997;17(suppl 2):13-16.
39. Gotloib L, Shostak A, Wajsbrot V: Effects of osmotic agents upon the in vivo exposed mesothelial monolayer. Perit Dial Int 2000;20(suppl 2):11-14.
40. Gotloib L, Shostak A, Wajsbrot V, Kushnier R: High glucose induces a hypertrophie, senescent mesothelial cell phenotype after long in vivo exposure. Nephron 1999;82:164-173.
41. Pischetsrieder M: Chemistry of glucose and biochemical pathways of biological interest. Perit Dial Int 2000;20(suppl 2):26-30.
42. Kjellstrand P, Martinson E, Wieslander A, Holmquist B: Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: Influence of time and temperature. Perit Dial Int 1995;15:26-32.
43. Martinson E, Wieslander AP, Kjellstrand PT, Boberg U: Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose. ASAIO J 1992;38:M370-M372.
44. Wieslander AP, Kjellstrand PT, Rippe B: Heat sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations. Perit Dial Int 1995;15:S52-S59.
45. Nilsson Thorell CB, Muscalu N, Andren AH, Kjellstrand PT, Wieslander AP: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993;13:208-213.
46. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A: 3,4-Dideoxyglucosone-3-ene (3,4-DGE): A cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002;62:697-703.
47. Henderson IS, Couper IA, Lumsden A: Potentially irritant glucose metabolites in unused CAPD fluid; in Maher JF, Winchester JF (eds): Frontiers in Peritoneal Dialysis. New York, Field, Rich & Associates Inc, 1986, pp 261-264.
48. Henderson IS, Couper IA, Lumsden A: The effect of shelf life of peritoneal dialysis fluids on Ultrafiltration in CAPD; in La Greca G (ed): Peritoneal Dialysis. Milan, Wichtig, 1986, pp 85-86.
49. Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC: Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991;40:77-79.
50. Wieslander AP, Andren AH, Nilsson Thorell C, Muscalu N, Kjellstrand PT, Rippe B: Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995;15: 348-352.
51. Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ: Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 1997; 17:373-378.
52. Sundaram S, Cendoroglo M, Cooker LA, Jaber BL, Faict D, Holmes CJ, Pereira BJ: Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro. Am J Kidney Dis 1997;30: 680-689.
53. Jonasson P, Braide M: Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages. Perit Dial Int 1998;18:376-381.
54. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-739.
55. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12: 2434-2441.
56. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
57. Lamb EJ, Cattell WR, Dawnay AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995;47:1768-1774.
58. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T: Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heatsterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999; 19:325-333.
59. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, Uchida K, Saito A, Van Ypersele DS, Kurokawa K: Advanced glycation and lipid oxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58:425-435.
60. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K, Horiuchi S: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999;14:1541-1549.
61. Wieslander A, Linden T: Glucose degradation and cytotoxicity in PD fluids. Perit Dial Int 1996; 16(suppl 1):114-118.
62. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, Pischetsrieder M: In vitro formation of N(s)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001;280:1408-1414.
63. Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J: Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998;54:1731-1738.
64. Feriani M, Carobi C, La Greca G, Buoncristiani U, Passlick Deetjen J: Clinical experience with a 39mmol/l bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 1997;17:17-21.
65. Feriani M: Bicarbonate-buffered CAPD solutions: From clinical trials to clinical practice. Perit Dial Int 1997;17(suppl 2):51-55.
66. Mackenzie RK, Holmes CJ, Moseley A, Jenkins JP, Williams JD, Coles GA, Faict D, Topley N: Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNF-a secretion. J Am Soc Nephrol 1998;9:1499-1506.
67. Mackenzie RK, Jones S, Moseley A, Holmes CJ, Argyle R, Williams JD, Coles GA, Pu K, Faict D, Topley N: In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kidney Dis 2000;35:112-121.
68. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Friedberg M, Wieslander A: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
69. Tranaeus A: A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000;20:516-523.
70. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, Wrege U, Grontoft KC, Larsson R, Berglund J, Tranaeus AP, Faict D: Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998;53:1061-1067.
71. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, Williams JD, Coles GA, Topley N: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001;59:1529-1538.